Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.
Actively Recruiting
Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are evaluating the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke who are undergoing endovascular thrombectomy. This phase 2, multicenter, randomized, double-blind, placebo-controlled study aims to understand how this drug affects patients treated within 24 hours of stroke onset. The trial involves adult participants aged 18 to 80 years with specific types of large-vessel occlusion in the brain. Participants will be randomly assigned to receive either anisodine hydrobromide or a placebo, both given alongside standard endovascular thrombectomy care. The drug is administered as an intravenous infusion of 2 mg diluted in saline twice daily for a total of 14 doses. The placebo group receives an equivalent volume of saline infusion on the same schedule. Both groups will be monitored during follow-up to assess treatment effects and safety. During the study, participants will undergo regular evaluations including neurological assessments using NIH Stroke Scale and modified Rankin Scale scores, along with brain imaging to measure cerebral infarct volume on day 8. Additional outcome measures at 90 days include functional independence and quality of life assessments. Safety is closely monitored, and participants are followed until study completion in March 2027.
Actively Recruiting
Researchers are evaluating the progression-free survival of D-1553 Tablet compared to Docetaxel Injection in patients with KRAS G12C mutation-positive locally advanced or metastatic non-small cell lung cancer NSCLC who have not responded to prior standard therapy. This phase III, randomized, controlled, double-blind study aims to assess progression-free survival as the primary endpoint, with other outcomes measured over up to three years. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Participants will receive either the experimental D-1553 Tablet or the active comparator Docetaxel Injection, each administered in 21-day treatment cycles. D-1553 is a KRAS inhibitor, while Docetaxel is an anti-tumor drug that works by affecting microtubule dynamics. The study design includes a quadruple masking and random allocation to ensure unbiased results. During the study, participants will undergo evaluations of progression-free survival, overall survival, response rates, disease control, and patient-reported outcomes over a period of up to three years. Safety assessments include monitoring adverse events and laboratory tests from consent through 30 days after the last dose. Pharmacokinetic parameters such as time to maximum plasma concentration and half-life will be measured during specific cycles. The total participation duration depends on individual treatment response and follow-up.
Actively Recruiting
This research aims to assess whether immunonutrition can reduce oral mucositis compared with standard nutrition in patients with locally advanced nasopharyngeal carcinoma receiving chemoradiotherapy. Oral mucositis is a common and severe side effect in these patients, causing pain, difficulty swallowing, and malnutrition, which can disrupt treatment and worsen quality of life and prognosis. Nutritional interventions like immunonutrition may help improve immune response, reduce inflammation, and enhance treatment tolerance and outcomes. Participants receive induction chemotherapy with gemcitabine and cisplatin followed by concurrent chemoradiotherapy with intensity-modulated radiotherapy and cisplatin. They are randomly assigned to one of two groups one group receives enteral immunonutrition Oral Impact twice daily starting 5 days before radiotherapy until treatment ends, while the other group receives a standard enteral nutrition formula ENSURE three times daily over the same period. During the study, participants are monitored for the incidence, timing, and duration of severe oral mucositis over 7 weeks. Researchers also assess immune status, inflammatory markers, nutritional and physical function, quality of life, and survival rates up to 2 years after randomization. Safety and adverse events are recorded throughout the study. Participants are expected to follow scheduled visits, laboratory tests, and questionnaires.
Actively Recruiting
Researchers are evaluating whether supplementing very preterm infants born before 29 weeks of gestation with pasteurized donor human milk pHDM or preterm formula PTF when their own mothers milk OMM is insufficient can improve survival without surgery-requiring necrotizing enterocolitis NEC by 34 weeks corrected gestational age. The study also assesses if routine use of human milk fortifiers is better than selective use based on growth faltering. This trial is a multicenter, double-randomized, open-label trial conducted alongside routine neonatal care, aimed at improving both short- and long-term outcomes in this vulnerable population. Participants will be randomized twice first, within the first week of life to receive either pHDM or PTF as supplemental feeding if OMM is insufficient second, during the second week of life to receive either routine fortification of human milk or selective fortification only if growth faltering occurs. Feeding and care follow standard clinical practice throughout the study. Two groups are compared to determine which supplement and fortification strategy better supports survival and neurodevelopment. During the study, participants will undergo feeding and care according to routine practice, with neurodevelopmental assessments performed at 2 years corrected age using the Griffiths Mental Development Scales. Researchers will measure survival without surgical NEC at 34 weeks corrected age as the primary outcome, along with various secondary outcomes including survival during hospitalization, NEC incidence, infections, growth parameters, and brain injury. The study continues until the infants reach 2 years corrected age to assess long-term development and health.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of TQA2225AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis NASH. It is a randomized, double-blind, placebo-controlled Phase II study designed to assess how well two different doses of this treatment work in managing NASH, a liver condition characterized by fat buildup and inflammation. Participants will receive either 25mg or 50mg of TQA2225AP025 or a matching placebo, given by weekly subcutaneous injections for 48 weeks. The study includes two experimental groups receiving the different doses, and all treatments are administered under blinded conditions to assess the treatment effects accurately. During the study, participants will undergo liver biopsies at the start and after 48 weeks to measure changes in liver condition using the NASH CRN scoring system. Safety will be closely monitored by tracking any adverse events throughout the treatment period. The study is expected to provide detailed information on both the treatment impact on liver health and its safety profile over nearly a year of participation.
Actively Recruiting
Researchers are studying the effects and safety of SR1375 in hospitalized adults with community-acquired pneumonia CAP. This phase 2, randomized, double-blind, placebo-controlled study aims to evaluate SR1375 compared to placebo in patients who have not improved after initial standard pneumonia treatment. The study includes adults aged 18 to 85 years and is sponsored by Shanghai SIMR Biotechnology Co., Ltd. Participants will be randomly assigned to one of four groups to receive either 0.3 mg, 1 mg, or 3 mg of SR1375 capsules or a placebo daily by mouth for 8 weeks, alongside their usual pneumonia treatments. The study includes a screening period, an 8-week double-blind treatment period, and a 14-day safety follow-up after treatment ends. During the study, participants will undergo assessments including the NIAID-OS 8-point scale to monitor pneumonia severity, oxygen levels, and other health measures up to 56 days. Researchers will track outcomes such as oxygenation, mortality, hospitalization duration, and readmission rates. The total participation time for each patient is up to 10 weeks, with close monitoring of safety and health status throughout the study.
Actively Recruiting
This research aims to evaluate the clinical efficacy and safety of combining luspatercept with low-dose thalidomide compared to using luspatercept alone in adults with transfusion-dependent b2-thalassemia major. This inherited blood disorder requires regular red blood cell transfusions and has limited treatment options, making this study important for improving patient care. The trial is a prospective, multicenter, randomized, double-blind, placebo-controlled phase 2 study. Participants are randomly assigned in a 11 ratio to either receive luspatercept combined with low-dose thalidomide or luspatercept with a placebo. Luspatercept is given at a starting dose of 1.0 mgkg every 21 days, while thalidomide or placebo is given daily at 50 mg. Both treatments last for 48 weeks, and participants may continue best supportive care like transfusions, iron chelation, and other therapies as needed. The study includes a screening period, treatment phase, and follow-up at weeks 12, 24, 36, and 48. During the study, participants undergo physical exams, vital sign checks, blood tests, transfusion tracking, iron level monitoring, quality-of-life assessments, and safety evaluations. Researchers measure how well the treatment reduces the need for blood transfusions, with the primary outcome focusing on transfusion reduction between weeks 13 and 24. Secondary outcomes assess longer-term transfusion reduction, iron metabolism, hemolysis, and adverse events. Data is collected throughout the treatment and follow-up periods for detailed analysis.
1-10 of 18
1